Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
ISSN: 2155-9899
Valentina Pop-Began, D Pop-Began, V Grigorean and C Popescu
Accepted Abstracts: J Clin Cell Immunol
Innate immune system is an universal form of host defense against infections. The recognition of the innate immunity is based on a limited number of encoded receptors that have evolved to recognize microbial metabolism products. Recognition of these molecular structures allows the immune system to distinguish own infectious components from non-communicable structures. Immune suppression is a hallmark of sepsis. The complement system is activated in the early stages of sepsis, generating large amounts of anaphylatoxin C5a. Complement and TLR family are two major upstream sensors and effectors systems of innate immunity. It was found that TLR4 and complement system are involved in initiating the inflammatory response in sepsis. Clinical studies in which TLR4 was blocked have not shown beneficial effects (41). Toll-like receptors (TLRs) that are a subfamily of PRRS have emerged as the crucial receptors for the recognition of DAMPs. Recently, in the complex cascade of sepsis was highlighted a special form of non-coding genetic material called microRNA. The individual role of every microRNA and the exact role of microRNA network is under investigation. Currently, studies are performed in order to find micro RNA to be used as biomarkers of sepsis. Researches are performed to determine microRNA, small fragments of non-coding RNA, in order to distinguish patients with sepsis and healthy patients, and if the plasma levels of microRNA correlate with the severity of the disease. Recent researches reports that the regulation of gene expression through microRNA plays a very important role in the following cellular processes, for example: Apoptosis, the differentiation process, and the cell cycle.
I am an M.D/PhD in Biology. I work currently in a laboratory of a Health Clinical Center, CHU of Lyon. I specialize in immuno-haematology as well as in NIPT: fetal RHD genotyping on maternal plasma. I was invited to present this at several international conferences (ESHG 2012) and I am the author of a recently published article (Non-invasive fetal RHD genotyping: Validation of the method with 200 patients, TCB, 2014 ).